STI-571

Imatinib Mesylate (STI-571) is a tyrosine kinase receptor inhibitor with antineoplastic activity (IC50s: 0.6 μM, 0.1 μM and 0.1 μM for v-Abl, c-Kit and PDGFR, respectively).

Imatinib (STI571) is a multi-targeted receptor tyrosine kinase inhibitor that selectively inhibits the kinase activities of BCR ABL, v-Abl, PDGFR, and c-kit with oral activity. Imatinib has antitumor activity for the treatment of chronic granulocytic leukemia.

Imatinib-d8 (STI571 D8) is a 2H-labeled version of Imatinib. Imatinib is a multi-target receptor tyrosine kinase inhibitor with anti-tumor activity, selectively inhibiting BCR-ABL, v-Abl, PDGFR, c-kit kinases, and is used in chronic myeloid leukemia treatment.